# Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

> **NCT00541281** · PHASE2 · COMPLETED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 150 (actual)

## Conditions studied

- Hormone Resistant Prostate Cancer
- Metastatic Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** estramustine
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00541281
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2009-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541281, "Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT00541281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*